Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May/Jun;11(4):632-638.
doi: 10.1080/19420862.2019.1583996. Epub 2019 Mar 21.

Controlled conductivity at low pH in Protein L chromatography enables separation of bispecific and other antibody formats by their binding valency

Affiliations

Controlled conductivity at low pH in Protein L chromatography enables separation of bispecific and other antibody formats by their binding valency

Chen Chen et al. MAbs. 2019 May/Jun.

Abstract

The complex molecular formats of recent therapeutic antibodies, including bispecific antibodies, antibody fragments, and other fusion proteins, makes the task of purifying the desired molecules in a limited number of purification steps more and more challenging. Manufacturing these complicated biologics can be substantially improved in the affinity capture stage if the simple bind-and-elute mode is accompanied by targeted removal of the impurities, such as mis-paired antibodies and oligomers or aggregates. Here, we report a method, based on the binding valency to Protein L resin, of separating proteins during the elution step by simply controlling the conductivity at low pH. We show that the method efficiently separated targeted antibodies from mis-paired and aggregated species. Notably, the number of Protein L binding sites can be built into the molecule by design to facilitate the purification. This method may be useful for purifying various antibody formats at laboratory and manufacturing scales.

Keywords: Immunoglobulin kappa light chain; Protein L; affinity purification; binding valency; conductivity.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Schematic representation of the structures of antibodies used in this study. Ab#1 is a bispecific antibody, Ab#2 is a monospecific bivalent antibody, and Ab#3 is a BiTE antibody that comprises two scFv fusion proteins. The target antigen of each paratope is described.
Figure 2.
Figure 2.
Separation of BsAbs by binding valency at various acidic pH while gradually decreasing the conductivity. Chromatograms show the separation of Ab#1 and Ab#2 at pH 2.4 (a), pH 2.7 (b), pH 3.0 (c), and pH 3.3 (d) while the NaCl concentration was gradually reduced from 100 mM to 0 mM. A wash of 1x PBS(−) was used before the elution step. A key in the figure gives the meaning of each line. The conductivity value at which peaks were seen at pH 2.7 and 3.0 are included in B and C.
Figure 3.
Figure 3.
Separation of BsAb based on binding valency at various acidic pH while reducing the conductivity in a stepwise manner. (a) Chromatograms show the separation of Ab#1 and Ab#2 at pH 2.7 while the conductivity was reduced in a stepwise manner. A 1x PBS(−) wash was used before the elution step. A key in the figure gives the meaning of each line. (b) The CIEX chromatogram of the samples derived from peak 1 and peak 2 in (A) are shown in dotted and slide lines, respectively. Range of the peak assigned for Ab#1 and Ab#2 is specified by each arrow and the content of each peak area is calculated as shown in the bottom panel. (c and d) The same set of experiments done in (a) were conducted at pH 3.0 (c) and the CIEX results are shown in (d).
Figure 4.
Figure 4.
Separation by conductivity elution of monomer and oligomer/aggregates of an antibody fragment in BiTE format. (a) A chromatogram by SEC-HPLC shows the rate of aggregates and monomers of Ab#3 at pH 2.7. (b) A chromatogram shows the separation of aggregates and monomers of Ab#3 by conductivity gradient elution. A key in the figure gives the meaning of each line. The conductivity value of each peak is described. Arrows show fractions that were selected for further analysis. (c) SEC-HPLC chromatograms of Ab#3 in fractions from peak 1 and peak 2 selected in b and its monomer rate is shown. The results of an analysis of the molecular weight marker (MWM) is also shown at the bottom.

Similar articles

Cited by

References

    1. Spiess C, Zhai Q, Carter PJ.. Alternative molecular formats and Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol. 2015;67(2Pt A):95–106. doi:10.1016/j.molimm.2015.01.003. - DOI - PubMed
    1. Vazquez-Lombardi R, Phan TG, Zimmermann C, Lowe D, Jermutus L, Christ D.. Challenges and opportunities for non-antibody scaffold drugs. Drug Discov Today. 2015;20(10):1271–83. doi:10.1016/j.drudis.2015.09.004. - DOI - PubMed
    1. Ishiguro T, Sano Y, Komatsu SI, Kamata-Sakurai M, Kaneko A, Kinoshita Y, Shiraiwa H, Azuma Y, Tsunenari T. Kayukawa Y and others. An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors. Sci Transl Med. 2017;9:410. doi:10.1126/scitranslmed.aal4291. - DOI - PubMed
    1. Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T, Yoshihashi K, Okuyama-Nishida Y, Saito H. Tsunoda H and others. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012;18(10):1570–74. doi:10.1038/nm.2942. - DOI - PubMed
    1. Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today. 2015;20(7):838–47. doi:10.1016/j.drudis.2015.02.008. - DOI - PubMed

Publication types

MeSH terms